View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 5, 2011

Ataluren Shows Efficacy for Cystic Fibrosis

PTC Therapeutics has announced the successful clinical results from a Phase II study of ataluren, a drug to treat adults with nonsense mutation cystic fibrosis. The trial, an extension of a short-term open-label Phase IIa proof-of-concept study, enrolled 19 patients and showed that atal

By cms admin

PTC Therapeutics has announced the successful clinical results from a Phase II study of ataluren, a drug to treat adults with nonsense mutation cystic fibrosis.

The trial, an extension of a short-term open-label Phase IIa proof-of-concept study, enrolled 19 patients and showed that ataluren induced improvements in chloride channel activity, cystic fibrosis-related cough and positive trends in lung function.

The drug also demonstrated combined mean improvements of forced expiratory volume in one second and forced vital capacity.

PTC Therapeutics chief medical officer Robert Spiegel said a 48-week, placebo-controlled Phase III study of ataluren in nonsense mutation cystic fibrosis patients is fully enrolled, with data expected to be available in the first half of 2012.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology